Bausch + Lomb Corporation
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Bausch + Lomb Corporation functions as a global leader in eye health, committed to enhancing and preserving vision. Its operations are structured across three distinct divisions: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health segment delivers an extensive portfolio of contact lenses, encompassing both daily disposable and planned replacement modalities, alongside essential lens care solutions. This division also provides a variety of over-the-counter eye drops, vitamins, and mineral supplements designed to address common conditions such as dry eye, allergies, and redness, including brands like Lumify and the recently acquired Blink portfolio. The Ophthalmic Pharmaceuticals division offers both branded and generic prescription medications for post-operative management and the treatment of numerous ocular conditions, including glaucoma, ocular hypertension, retinal disorders, and eye inflammation, further strengthened by the recent acquisition of Xiidra for dry eye. The Surgical division equips eye care professionals with advanced instruments and technologies for interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include sophisticated intraocular lenses and their delivery systems, phacoemulsification devices, and a comprehensive range of surgical tools, such as the enVista Envy IOL and Storz Ophthalmic Instruments. Established in 1853, the company maintains its corporate headquarters in Vaughan, Canada.
Company News
Bausch + Lomb Announces New Published Research on enVista Aspire™ Real World Experience
Most Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey Finds
Bausch + Lomb Advances Two First-in-Class Eye Health Therapies
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
Insider Sheds Nearly 53,000 Shares of Consumer Health Stock, Valued at Almost $900,000
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance
Bausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
Bausch + Lomb Q2 Earnings Call Highlights
Bausch + Lomb (BLCO) Q2 Earnings Meet Estimates
Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
New Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-Confidence
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bausch + Lomb Corporation (BLCO) Discusses Project Halo and Myopia Control Developments in Vision Care Transcript